LongeVC portfolio company Constructive Bio has appointed Boston-based biopharma leader Jim Weissman to its Board of Directors. Weissman brings decades of experience in biopharma, including scaling biotechnology platforms, building strategic industry partnerships, and helping translate breakthrough science into commercial therapeutic franchises.
The appointment comes as Constructive Bio commercially advances its whole-genome writing and engineered translation platform. The technology opens new ways to design and manufacture therapeutics using chemistries that fall outside what natural biology can produce.
His addition to the board signals where the company is heading: bringing in commercial and partnership expertise as the platform moves toward market.
Learn more about Constructive Bio here.
The appointment comes as Constructive Bio commercially advances its whole-genome writing and engineered translation platform. The technology opens new ways to design and manufacture therapeutics using chemistries that fall outside what natural biology can produce.
His addition to the board signals where the company is heading: bringing in commercial and partnership expertise as the platform moves toward market.
Learn more about Constructive Bio here.